INTERVIEW 101 wearing tight-fitting clothes, doing regular exercises, reducing weight, and taking PPI if necessary. Why Hepatitis B vaccine is not being prescribed to all patients, considering its availability and the high risk of chronic infection leading to cirrhosis and liver cancer posed by Hepatitis B virus infections? In 2005,the HBV vaccine was included in the EPI program, so all patients are not routinely prescribed the HBV vaccine, but those who were born before 2009 should be screened for hepatitis B and can get vaccinated. We very often hear about constipation among our population. Actually, what is the reason and management of this common disease? The meaning of constipation varies from person to person. Some may define it as the passage of hard stool whereas others may define it as difficulty or infrequent passage of stool. Lack of dietary fiber, inadequate water intake & less exercise are common causes of constipation. There are also other causes such as, GIT causes (colon cancer, TB, Crohn’s disease and anal fissure), endocrine causes (hypothyroidism, hypercalcemia), neurological causes (stroke, spinal cord injury, Alzheimer’s disease). The majority of patients are managed with diet and lifestyle changes like eating a high-fiber diet, drinking plenty of water, doing exercises in most days of the week, using good bowel habits. Sometimes medications may also be needed like, laxatives (laxatives are medicines that help move stool through the colon), enemas & suppositories, prescribed medicines (lubiprostone, linaclotide, plecanatide, and prucalopride) and pelvic muscle training. Some patients may need further investigations and treatment of underlying causes and some patients may require surgery to treat constipation. l Mere days after surgery, a patient who had a chronic spinal cord injury has made such a miraculous recovery that even the Minnesota neurosurgeon is left stunned. For the last year and a half, Bernard Hunter (the patient) has been paraplegic, but his medical journey goes back even further, starting with severe headaches few years ago. “I caught pneumonia. And then I had two strokes, a couple of seizures, and an aneurysm at work,” Hunter said. Doctors discovered a fungus called Blastomyces, which is found in moist soil such as in wooded areas and near waterways, had entered his lungs. Multiple surgeries later and Hunter was left unable to walk due to an infection in his spine that caused a cyst. “They had kind of given up on me, they said there was nothing else they could do,” said Hunter. Then, he was referred to a Neurosurgeon in Minnesota. Doctor successfully performed a surgery, where the doctor made an incision on the front of Hunter’s neck, cut into the layer overlaying the spinal cord, found the cyst and was able to poke holes in it. What the doctor didn’t expect, though, was what happened the next day. “There was a note in that chart that said that he walked 8 feet with physical therapy. And I thought, ‘OK, there has to be some sort of mistake.’ I went in to see him and I said, ‘Did you really walk 8 feet?’ And he said, ‘Here, let me show you.’ Then, he got up and walked again,” doctors said. On Wednesday, five days post-op, Hunter walked more than 100 feet. He is utterly relieved, as he thinks about all the things he loved that may soon be a possibility again. The patient’s family filled with gratitude toward the medical professional who helped Hunter makes these strides. Doctor said “I wish I could take full credit, but I have to say this is a category of medical miracle where I don’t completely understand why he got so much better, I no longer believe that there is such a thing as complete spinal cord injury. I feel like every patient has some level of capacity to recover, with perhaps a few exceptions, and it’s just a matter of figuring out what will work.” Hunter’s medical journey is proof of that, doctor added. l Source: Fox9 Patient with spinal cord injury walks day after surgery MEDICAL MIRACLE
Brand Name Generic Name Manufacturer Date of Approval Treatment Zevtera Ceftobiprole Medocaril Basilea Pharmaceutica Ltd. Apr 03, 2024 Treatment for Skin and Structure Infection Voydeya Tablets Danicopan AstraZeneca Mar 29, 2024 Treatment for Paroxysmal Nocturnal Hemoglobinuria Vafseo Tablets Vadadustat Akebia Therapeutics, Inc. Mar 27, 2024 Treatment forAnemia Due to Chronic Kidney Disease Winrevair for Injection Sotatercept Merck Mar 26, 2024 Treatment for Pulmonary Arterial Hypertension Opsynvi Tablets Macitentan and Tadalafil Actelion Pharmaceuticals US, Inc. Mar 22, 2024 Treatment for Pulmonary Arterial Hypertension. Duvyzat Oral Suspension Givinostat Italfarmaco Group Mar 22, 2024 Treatment for Duchenne Muscular Dystrophy Lenmeldy - formerly OTL-200 Atidarsagene Autotemcel Orchard Therapeutics Mar 18, 2024 Treatment for Metachromatic Leukodystrophy Rezdiffra Tablets Resmetirom Madrigal Pharmaceuticals, Inc. Mar 14, 2024 Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease Tevimbra Injection Tislelizumab-jsgr BeiGene, Ltd. Mar 13, 2024 Indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L) 1 inhibitor Wyost Injection Denosumab-bbdz Sandoz Inc. Mar 5, 2024 Treatment for Osteolytic Bone Lesions of Multiple Myeloma, Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy Jubbonti Injection Denosumab-bbdz Sandoz Inc. Mar 5, 2024 Treatment for Osteoporosis Jubbonti (denosumab-bbdz) is a RANK ligand (RANKL) inhibitor interchangeable biosimilar to Prolia (denosumab) used in the treatment of osteoporosis. Letybo Powder for Injection Letibotulinumtoxin A-wlbg Hugel, Inc. Feb 29, 2024 Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. Simlandi Injection Adalimumab-ryvk Alvotech and Teva Pharmaceutical Industries Ltd. Feb 23, 2024 Treatment for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, Uveitis Exblifep Injection Cefepime and Enmetazobactam Allecra Therapeutics Feb 22, 2024 Treatment of complicated urinary tract infections (cUTIs). Amtagvi Suspension for Intravenous Infusion Lifileucel Iovance Biotherapeutics, Inc. Feb 16, 2024 Treatment of adult patients with unresectable or metastatic melanoma. Aurlumyn Injection Iloprost Eicos Sciences Inc. Feb 13, 2024 Treatment of severe frostbite in adults to reduce the risk of digit amputations. Eohilia Oral Suspension - formerly TAK-721 Budesonide Takeda Pharmaceutical Company Limited Feb 09, 2024 Treatment of eosinophilic esophagitis. Zelsuvmi Topical Gel Berdazimer Sodium Ligand Pharmaceuticals Jan 05, 2024 Indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older. 102 FDA APPROVAL
FDA UPDATE 103 FDA approves first drug for common, Serious Liver Disease, Rezdiffra Livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra , to treat the condition, as per the U.S. Food and Drug Administration. The condition is called non-cirrhotic non-alcoholic steatohepatitis (NASH). NASH with liver scarring is thought to affect up to 8 million Americans. It’s often tied to high blood pressure and type 2 diabetes, the FDA explained in a statement. The approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise, Nokolov said in the FDA statement. As the FDA explained; Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation. Rezdiffra is made by Madrigal Pharmaceuticals and was approved based on data collected after a year as part of an ongoing 54-month trial. Based on the assessments of various pathologists who were examining patients liver scarring, between 24% and 36% of NASH patients taking 100 milligrams of Rezdiffra saw their NASH resolve and experienced no worsening of liver scarring, compared to 9% to 13% of those who received placebo, the FDA said. A similar ratio saw their NASH continuing but experienced no worsening of liver scarring, the agency said. However, Rezdiffra did come with side effects, including diarrhea and nausea, and its label includes warnings regarding a risk for drug-induced liver toxicity and gallbladder issues. Rezdiffra shouldn’t be taken by patients with a more advanced form of liver disease called decompensated cirrhosis, the FDA said, and the drug may interact with cholesterol-lowering statins, so patients should talk over the use of Rezdiffra with their doctor. l FDA Approves Tryvio (aprocitentan) for the combination treatment of resistant Hypertension Idorsia Pharmaceuticals U.S. Inc. announced that the US Food and Drug Administration (FDA) has approved Tryvio™ (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. l Xhance Approved by FDA as first and only medication indicated for treatment of adults with Chronic Rhinosinusitis without Nasal Polyps The U.S. Food and Drug Administration (FDA) has approved Xhance (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older. The approval was based on data from the ReOpen program evaluating Xhance for treatment of adults with chronic sinusitis. A drug-device combination product, Xhance uniquely combines a widely used nasal steroid with the Exhalation Delivery System™, an innovative delivery system designed to target the sites where inflammation occurs, especially difficult- toaccess sinuses and sinonasal drainage tracts not typically reached by standard-delivery nasal sprays. The safety profile and tolerability of Xhance for patients in the ReOpen trials was generally consistent with its currently labeled safety profile. The most common adverse reactions (incidence ≥ 3%) in the ReOpen program were epistaxis, headache, and nasopharyngitis. l FDA approves Praluent (alirocumab) injection to treat children with genetic form of High Cholesterol The U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDLC) lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). “Many children with heterozygous familial hypercholesterolemia (HeFH) are able to substantially improve their LDL-C (bad cholesterol) with currently available therapies. But for those children whose LDL-C remains dangerously high, this approval is an important milestone as it gives these children and their families an additional option to help reduce and manage their LDL-C levels much earlier in their lives,” said Chief Medical Officer of the Family Heart Foundation. The approval is based on a Phase 3, randomized multicenter trial evaluating pediatric patients aged 8 to 17 with HeFH, who had LDLC levels of 130mg/dL or greater and were already being treated with lipid-lowering medications. Patients who received Praluent every four weeks had 31% lower LDLC than placebo at 24 weeks. Improvements in additional key lipid parameters were also observed. No new adverse reactions were identified in this trial, and the safety profile was consistent with the safety profile observed in adults with HeFH. l FDA approves Wegovy for Cardiovascular risk reduction in people with overweight or obesity and established Cardiovascular disease The US Food and Drug Administration (FDA) has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established cardiovascular disease (CVD). The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy®statistically significantly reduced the risk of MACE by 20% compared to placebo when added to standard of care. The exact mechanism of cardiovascular risk reduction has not been established. «We are very pleased that Wegovy® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks,» said executive vice president and head of development at Novo Nordisk. “This approval is an important milestone for people living with obesity and cardiovascular disease, as the SELECT data demonstrated that Wegovy® has the potential to prolong lives by addressing some of the leading causes of preventable deaths by reducing the risks of cardiovascular events.” Novo Nordisk has also filed for a label expansion in the EU, and a decision is expected in 2024. l
104 APPOINTMENTS & PROMOTIONS Md. Ibrahim Rashed has recently been promoted as Assistant General Manager, Sales & Marketing of Sharif Pharmaceuticals Ltd. Prior to this, he was Manager, Sales & Marketing in the same organization. He obtained his post-graduation in business faculty and has vast knowledge in Pharma Sales & Marketing. Taz Md. Aga Menon has recently been promoted to Senior Manager under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as Manager in the same organization. He started his career at Opsonin Pharma Ltd in 2007. He completed his B .Pharm and M .Pharm from Jahangirnagar University (JU). Md. Nasir Uddin Mahmood has recently been promoted to Manager under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as a Deputy Manager in the same organization. He started his career at Opsonin Pharma Ltd in 2010. He completed his B. Pharm from University of Science and Technology, Chittagong (USTC) and M. Pharm from State University Bangladesh (SUB). Md. Rezwanul Islam has recently been promoted as Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Deputy Manager, PMD in the same organization. Prior to this, he worked in Ziska Pharma as Senior Brand Executive. He obtained his B. Pharm from Stamford University and M. Pharm (Pharmaceutical Marketing) from University of Development Alternative. Md. Mahfuzur Rahman has recently been promoted as Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Deputy Manager, PMD in the same organization. Prior to this, he worked in Ziska Pharma as Senior Brand Executive. He obtained his B. Pharm from Khulna University and M. Pharm (Pharmaceutical Marketing) from University of Development Alternative. He has vast knowledge over 15 years in Pharmaceutical Marketing specially in Anti-Ulcerant & Steroid Portfolio. Md. Mahbubur Rahman has recently been promoted as Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Deputy Manager, PMD in the same organization. He Obtained his B. Pharm from Stamford University, M. Pharm from University of Development Alternative and MBA from University of Gloucestershire, UK. He has vast knowledge over 15 years in Pharmaceutical Marketing specially in Antibiotic & NSAID Portfolio and is a specialist in new product launching & brand building activity. Dipak Kumar Saha has recently joined Team Pharmaceuticals Ltd. as Executive Director, Marketing. Starting his career from Eskayef Bangladesh Ltd. in 1998 as Product Executive, he worked in Square, Aristopharma, Popular and Ziska Pharmaceuticals ltd. in different capacities. He has more than 25 years of experience in pharmaceutical marketing with diversified product range including Chronic Care Products, Ophthalmics, Hormones, Vaccines, Infusions & Animal Health Products. Dipak completed his B. Pharm, M. Pharm & MBA from University of Dhaka.
APPOINTMENTS & PROMOTIONS 105 Md Abu Sina has recently joined as “Deputy Manager, Corporate Affairs, Company Secretariat & Share Department” at Biopharma Limited. He has 17 years of experience in sales & distribution, trade channel development, territory business development, emerging segment, BI and trade marketing at the leading telecommunications service provider in Bangladesh, Grameen Phone Ltd. Md. Tanjib Hossain Shaki has recently been promoted to Assistant Manager under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as a Group Coordinator in the same organization. He started his career at Opsonin Pharma Ltd in 2012. He completed his B. Pharm and M. Pharm from East West University (EWU). Kazi Nazmul Hossain has recently been promoted as Assistant Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Product Manager, PMD in the same organization. Prior to this, he worked in Ziska Pharma as Brand Executive. He obtained his B. Pharm from Stamford University and M. Pharm from Asia Pacific University. Sazzad Hossain Chowdhury has recently been promoted as Assistant Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Product Manager, PMD in the same organization. Prior to this, he worked in Ziska Pharma as Brand Executive. He obtained his B. Pharm from Stamford University and M. Pharm from Jagannath University. Sabbir Ahmed has recently been promoted as Assistant Manager, Product Management Department (PMD) at Biopharma Limited. He joined Biopharma Limited as an Senior Executive in the Product Management Department last year. He started his career at Orion Pharma Limited in 2018, worked at Nuvista Pharma Limited (Subsidiary of Beximco Pharma Limited) and also worked at Asiatic Group. Sabbir Ahmed completed his B. Pharm and M. Pharm from North South University. Md. Tansir Ahmed has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2017. He completed his B. Pharm from Daffodil International University and M. Pharm from State University of Bangladesh. Sheik Md. Saiful Islam has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2017. He completed his B. Pharm and M. Pharm from State University Bangladesh (SUB). Md Nazmol Alam has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2018. He completed his B. Pharm and M. Pharm from Daffodil International University (DIU).
106 APPOINTMENTS & PROMOTIONS Shah Md Mouazzam Hossain has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Product Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2018. He completed his B. Pharm and M. Pharm from State University of Bangladesh (SUB). Md Anwar Hossain has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2018. He completed his B. Pharm and M. Pharm from Stamford University Bangladesh (SUB). Abdullah Al Noman has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2018. He completed his B. Pharm from University of Science & Technology Chattagram and M. Pharm from North South University. Md. Abdur Rashid has recently been promoted as Group Coordinator under Product Management Department (PMD) at Opsonin Pharma Ltd. Prior to this, he worked as an Senior Executive in the same organization. He started his career at Opsonin Pharma Ltd in 2018. He completed his B. Pharm and M. Pharm from University of Asia Pacific (UAP). Md. Ruhul Amin has recently been promoted as Product Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Senior Executive, PMD in the same organization. Prior to this, he worked in Biopharma as an Executive. He obtained his B. Pharm from Stamford University, M. Pharm from State University and PGDMM from Bangladesh Institute of Management. Md. Ferdous Alam Sazzad has recently been promoted as Product Manager, PMD at Sharif Pharmaceuticals Ltd. Previously, he was Senior Executive, PMD in the same organization. Prior to this, he worked in Monico Pharma as an Product Executive. He obtained his B. Pharm from IIUC, Chattogram and M. Pharm from North South University. Abu Hanif has recently joined as Sr. Executive in the International Business Department (IBD) at Biopharma Limited. He started his career as Quality Assurance Officer at Drug International Ltd. from 2020. He also worked in ACI Healthcare Limited as an Executive in the R & D (Formulation) Department from 2022 to 2023. He obtained his B. Pharm & M. Pharm from North South University. Omar Faruk Shuvo has recently been promoted to Senior Product Executive, Product Management Department (PMD) at Biopharma Limited. He joined Biopharma Limited as an Executive in 2020. He completed his B. Pharm and M. Pharm from Daffodil International University.
APPOINTMENTS & PROMOTIONS 107 Sabrina Sultana Faria has recently joined as an Executive in the International Business Department (IBD) at Biopharma Limited. She completed her B. Pharm (Professional) from Southern University. Anika Islam has recently joined as Brand Executive, SBMD at Everest Pharmaceuticals Ltd. Anika completed her B. Pharm (Professional) from North South University. Md Masum Ahmmed has recently joined as Brand Executive, SBMD at Everest Pharmaceuticals Ltd. Masum completed his B. Pharm (Professional) from Jahangirnagar University. Md. Tushar Imran has recently joined as Brand Executive, Strategic Brand Management Department (SBMD) at Everest Pharmaceuticals Ltd. Tushar completed his B.Pharm from Jahangirnagar University. CONGRATS Such achievements in cardiac research are a matter of great honor and pride for Bangladesh National Heart Foundation Hospital and Research Institute’s Clinical Research Team has received international recognition as ‘Best Clinical Research Team’. CERC officially presented this award to Prof. Fazila-Tun-Nesa Malik, the head of the team, recently at the world’s largest cardiology conference Euro PCR held in Paris, France. Only Bangladesh has received this honor in the Asian continent along with several other countries in the world. CERC (European Cardiovascular Research Center) is one of the world’s largest European-based multinational research organizations. National Heart Foundation of Bangladesh is a non-profit, charitable, government-aided organization. In 1978, the pioneer of heart disease treatment in Bangladesh, National Professor Brig. (Retd.) Abdul Malik established this foundation. For the last 46 years, this institution has been working relentlessly in the prevention, control, research and treatment of heart disease in Bangladesh. l
UPCOMING EVENTS 24 109 N.B. Dates/Venues of forthcoming events are subject to change/cancellation etc. with or without notice. So, intending participants are advised to check all details relating to VISA and other relevant matters before departure. Event Venue Date PharmaLytica 2024 Hyderabad, India May 30–June 01, 2024 BIO International Convention San Diego, CA June 03–06, 2024 Pharma TechAsia 2024 Bangkok, Thailand June 12–15, 2024 CPHI & PMEC China 2024 Shanghai, China June 19–21, 2024 International Healthcare & Medical conference 2024 Calgary, Canada June 21–25, 2024 BioPharma Expo 2024 Tokyo, Japan June 26–28, 2024 CPHI South East Asia Bangkok, Thailand July 10–12, 2024 Medlab Asia 2024 Bangkok, Thailand July 16–18, 2024 Pharma India Expo 2024 Hyderabad, India. July 18–20, 2024 14th Int. Healthcare, Hospital Management, Nursing & Patient Safety Conf.2024 Abu Dubai, UAE July 25–27, 2024 INALAB 2024 Indonesia, Jakarta July 30–Aug. 01, 2024 Vietnam Medi-Pharm Expo 2024 Ho Chi Minh, Vietnam Aug. 01–03, 2024 PhilMedical Expo 2024 Pasay, Manila Aug 14–16, 2024 CPHI Korea 2024 COEX, Seoul Aug 27–29, 2024 Nigeria Pharma Manufacturers’ Expo 2024 Lagos, Nigeria Sept. 03–04, 2024 Pharmaconex 2024 Egypt, Cairo Sept 08 –10, 2024 Medical Fair Asia 2024 Singapore, Singapore Sept 11–13, 2024 Pharma Pro&Pack Expo 2024 Hyderabad, India Sept 16–18, 2024 CPHI Europe 2024 Milan, Italy Oct 08–10, 2024 CPHI India 2024 Noida, India Nov 26–28, 2024 CPHI Middle East 2024 Malham, Saudi Arabia Dec 10–12, 2024 Pharmapack Europe 2025 Paris, France Jan 22–23, 2025 Asia Pharma Expo 2025 Dhaka, Bangladesh Feb. 28–Mar. 01, 2025 Medical Fair India 2025 New Delhi, India Mar 20–22, 2025 CPHI Japan 2025 Tokyo, Japan Apr 09–11, 2025 Event Venue Date 17th International Conference and Exhibition on Pharmacovigilance & Drug Safety 2024 Rome, Italy June 13–14, 2024 Pharmacovigilance Risk Assessment Committee (PRAC) Amsterdam, Netherlands July 08-11, 2024 Pharmacovigilance Risk Assessment Committee (PRAC) Amsterdam, the Netherlands 30 Sep-03 Oct 2024 2024 ISPE Annual Meeting & Expo Orlando, USA Oct 13-16, 2024 UPCOMING PHARMACOVIGILANCE EVENTS-2023-24
110 PRE-EVENT PharmaLytica Expo, the flagship event within South India’s pharmaceutical industry, is eagerly approaching its milestone 10th edition, scheduled from May 30th to June 1st, 2024, at HITEX, Hyderabad a prominent pharmaceutical hub in India. Organised by Informa Markets in India, this event marks a decade of excellence, providing a vital business platform for showcasing the latest industry trends, innovations, and business opportunities across Pharma Machinery & Packaging, Lab Analytical & Cleanroom, and Pharma Ingredients segments. Bringing together industry leaders, innovators, and stakeholders, PharmaLytica serves as a hub for exploring the forefront of India’s thriving pharmaceutical landscape. In its upcoming 10th edition, PharmaLytica 2024 anticipates the participation of more than 200 exhibitors and brands from across the country, including major industry players such as Schneider Electric, Integrated Cleanroom Technology, Nicomac Taikisha Clean Rooms, HLE Glascoat Ltd, Scientific Research Instruments Company, Ami Polymer & many more. Furthermore, the event enjoys robust support from esteemed associations like BDMAI, FOPE and Telangana Life Sciences. Speaking on the announcement of PharmaLytica 2024, Mr. Yogesh Mudras, Managing Director, Informa Markets India said, “We are delighted to embarked upon the decade long exciting journey of PharmaLytica, a path that has been dynamic, exciting, and nurtured the direction of the industry. As we scale up with passion and conviction, we recognize the pivotal role of this platform in nurturing industry direction. The growth of India’s pharmaceutical and healthcare sectors within the Vikasit Bharat economic blueprint hinges on valuedriven innovation and research, global supply chain integration, and equitable access. A Comprehensive and Engaging event Renowned for introducing cutting-edge innovations and facilitating knowledge exchange, PharmaLytica, apart from the business on the show floor, will host conferences, digital marketplaces, targeted meeting places, seminars, and workshops led by industry experts. Reflecting current trends, regulatory issues, and policies, PharmaLytica 2024 will spotlight innovations, challenges, and future directions within the pharmaceutical sector. An exclusive twoday conference, PharmaLytica 2024, with a theme of “Optimizing Pharmaceutical Quality and Compliance,” will bring together over 30 key industry figures for strategic discussions on the future of the pharmaceutical sector. l The Middle East is set to witness the unrivalled force of the pharmaceutical sector as it hosts the 6th ARAB PHARMA MANUFACTURERS’ EXPO 2024, the region’s largest & premier exhibition on comprehensive Pharma Manufacturing. The 6th ARAB PHARMA MANUFACTURE EXPO 2024 serves as the epicentre of strategic collaboration, uniting industry leaders and visionaries to propel the future of pharmaceutical development across the Middle East region. This landmark event boasts: The exclusive collaboration with the Arab Union of the Manufacturers of Pharmaceutical and Medical Appliances (AUPAM), making it the sole exhibition of its kind. The prestigious endorsement of the Arab Company for Drug Industries and Medical Appliances (ACDIMA), a Pan-Arab Shareholding company established by a resolution from the Arab Economic Unity Council. A prestigious line-up of over 250 exhibitors from 25+ countries, unveiling cutting-edge products, revolutionary technologies, and unparalleled services. Dr. Mohammad Khalil, Director General, ACDIMA extends his wholehearted support to AUPAM and the 6th ARAB PHARMA EXPO 2024, “We cordially invite all professionals from our manufacturing and clinical teams to seize the invaluable opportunities presented by this significant exhibition and conference, right at our doorstep. Best wishes to all participants!”. Prof. Dr. Nizar Mhaidat, Director General, Jordan Food & Drug Administration (JFDA), expressed, ‘JFDA proudly extends its unwavering support, and I cordially invite esteemed Arab FDA department heads and leaders from the pharmaceutical industry to join us at the expo and engage in the enlightening scientific program on July 2 and 3.’ Furthermore, the expo garners support from other notable associations across burgeoning markets, including the Jordan Chamber of Industry, Amman Chamber of Industry, Syria Scientific Council for National Pharmaceutical Industries, the Iraqi League for Medicine Producers, the Association Tunisienne des Médicaments Génériques, and the Engineering Export Promotion Council (EEPC) under the Ministry of Commerce, Government of India. l PharmaLytica 2024 The 6th Arab Pharma Manufacturers’ Expo 2024
POST-EVENT 111 Key decision-makers mark their presence at Analytica Anacon India & India Lab Expo 2024, in Mumbai attracted by its focus on automation & sustainability The recent Mumbai edition of analytica Anacon India and India Lab Expo, organised jointly by Messe Muenchen India and the Indian Analytical Instruments Association (IAIA), concluded successfully with satisfied exhibitors and delighted visitors who benefitted from various targeted experiences such as the technical conferences, hosted buyer program, prefixed buyer- seller meetings, and much more. Some of the leading exhibitors at this edition are Kewaunee Labway India Pvt. Ltd., Agilent Technologies India Pvt. Ltd., Shimadzu Analytical (India) Pvt. Ltd., Newtronic Lifecare Equipment Pvt. Ltd., Labguard India Pvt. Ltd., and many others. Certifications and regulatory authorities who participated in exhibition and conferences are Food and Drug Control Administration (FDCA), Indian Pharmacopoeia Commission (IPC), United States Pharmacopeia (USP), National Accreditation Board for Testing and Calibration Laboratories (NABL), and many others. Dr. Hemant G. Koshia, Commissioner, Food and Drugs Control Administration (FDCA), said, “The pharma industry is technology-driven and dependent on innovative laboratory solutions. Without them, producing high-quality drugs and maintaining efficient manufacturing is impossible. analytica Anacon India and India Lab Expo is a great platform to explore the latest advancements in laboratory technologies. Here I witnessed innovative technologies shaping the future of pharmaceuticals. Beyond the technology showcase, the trade fair is a great platform for knowledge sharing and learning through its thought-provoking panel discussions.” Regarding the success of this edition, Chandrahas Shetty, President, Indian Analytical Instruments Association (IAIA), said, “We have been representing the interests of the analytical instruments industry in India since close to two decades now. Over the years, we have represented the business interests of our member companies at various international forums as well as through these exhibitions and conferences across India. The phenomenal success of this Mumbai edition is a culmination of the strong professional relationships we have developed with the organisers as well as all industry stakeholders. We are glad to witness the powerful ideas discussed at this forum, and we hope to see more meaningful partnerships in the near future.” Commenting on the growth of the Mumbai edition, Bhupinder Singh, CEO, Messe Muenchen India, said, “We are delighted to see that this edition has emerged as a leading platform in the western region of India. With 63.5% growth in exhibition space and participation from distinguished personalities in the analytical technologies sector, this edition is a stepping stone to the upcoming edition in Hyderabad, the pharma hub of India. We look forward to witnessing more pioneering technologies at this upcoming edition, and we express gratitude to all our partners who have contributed meaningfully to the growth and competitiveness of the Mumbai edition.” l l 6024 high quality trade visitors attracted by 165 exhibitors displaying 3000 products & solutions. l 8,500 sqm of exhibition space making it the largest Mumbai edition ever. l 300 buyer-seller meetings, including hosted buyers from across India. l Technical conferences covered topics such as laboratory analysis, automation, regulatory compliance, sustainability, and many others. l analytica Anacon India and India Lab Expo was held from 15-17 April 2024 at the Bombay Exhibition Centre, Mumbai.